Interpreting FibroScan Results for Liver Fibrosis

Technical Validity and Pre-Test Requirements

The American Association for the Study of Liver Diseases recommends that FibroScan measurements meet technical validity criteria, including ≥10 successful measurements obtained, to ensure reliable results 1
The European Association for the Study of the Liver states that a minimum of 3-4 hours fasting is mandatory before FibroScan testing to avoid falsely elevated liver stiffness values 2, 3, 4
Food ingestion within 3-4 hours of testing falsely elevates liver stiffness values, regardless of the measurement method 2

For patients with non-alcoholic fatty liver disease (NAFLD), a FibroScan result of <8.0 kPa rules out advanced fibrosis with 93% sensitivity, according to the American Association for the Study of Liver Diseases 5, 1
The American College of Gastroenterology recommends that a FibroScan result of 8.0-8.2 kPa be used as the threshold for significant fibrosis (≥F2) in NAFLD patients 5, 1
For patients with chronic viral hepatitis, a FibroScan result of >7.0 kPa indicates significant fibrosis (≥F2), as stated by the American Association for the Study of Liver Diseases 5
The European Association for the Study of the Liver recommends that a FibroScan result of >12.5 kPa be used to diagnose cirrhosis in patients with chronic viral hepatitis 5

Active hepatic inflammation, such as acute hepatitis, can produce falsely cirrhotic-range values, according to the American Association for the Study of Liver Diseases 2
Obstructive cholestasis, right heart failure, and recent food ingestion are critical confounding factors that can falsely elevate FibroScan results, as stated by the European Association for the Study of the Liver 2, 3, 4

For patients with a FibroScan result of <8.0 kPa, the American College of Gastroenterology recommends repeat surveillance in 2-3 years if metabolic risk factors persist, and in 3-5 years if risk factors are well-controlled 5, 1
For patients with a FibroScan result of 8.0-12.0 kPa, the American Association for the Study of Liver Diseases recommends more aggressive management to prevent progression, and consideration of hepatology referral depending on the underlying disease 5, 1, 6
For patients with a FibroScan result of >12.0-12.5 kPa, the European Association for the Study of the Liver recommends urgent hepatology referral and initiation of hepatocellular carcinoma (HCC) screening 5, 1

The American Association for the Study of Liver Diseases recommends sequential testing using FIB-4 followed by FibroScan for indeterminate scores, as this approach is more accurate than either test alone 1, 6
For adults with chronic liver disease, the European Association for the Study of the Liver recommends calculating FIB-4 first, and then proceeding to FibroScan if the FIB-4 score is indeterminate (1.3-2.67) 5, 6

The American Association for the Study of Liver Diseases defines a FibroScan value ≥ 8.0 kPa as indicating significant fibrosis (stage ≥ F2). 7
The American Association for the Study of Liver Diseases sets the threshold for advanced fibrosis (stage ≥ F3) at ≥ 10.5 kPa. [8][9]10
The same society defines cirrhosis (stage F4) as a FibroScan value ≥ 16 kPa. [8][9]10

The American Gastroenterological Association recommends that patients whose FibroScan is < 8.0 kPa undergo repeat elastography in 2–3 years if metabolic risk factors (e.g., diabetes, obesity, metabolic syndrome) persist, or in 3–5 years if those risk factors are well controlled. 7

Active hepatic inflammation (e.g., acute hepatitis) can cause overestimation of liver stiffness on FibroScan. 8
Right‑sided heart failure may also elevate FibroScan measurements independent of fibrosis. 8

Presence of metabolic syndrome is associated with a higher likelihood of fibrosis progression. 8
Chronic infection with hepatitis B or hepatitis C viruses increases the risk of advancing liver fibrosis. 8